The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ETFs? The ...

Discover 2026 stock market outlook: earnings-driven gains, potential sector rotation, biotech opportunities, and Fed policy ...

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the ...

The AI trade has been wobbling quite a bit in recent weeks, to say the least. And while the popping of the AI bubble hasn’t ...

Payable Dec 26; for shareholders of record Dec 22; ex-div Dec 22. More on VanEck Biotech ETF SA Quant ranks Goldman's health ...

Traders should base analysis on the underlying index (XBI), as LABU's price action is distorted by leverage-induced drift.

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.

Biotech ETFs have had a banner year, earning some investors returns north of 30 percent since January. I say “some investors” because, it turns out, not all biotech ETFs are created equal. In our 2012 ...